Racura Oncology Ltd (ASX:RAC)

Market Cap	398.02M +27.2%
Revenue (ttm)	2.81M -46.5%
Net Income	-11.09M
EPS	-0.06
Shares Out	196.07M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	141,261
Open	2.040
Previous Close	2.030
Day's Range	1.980 - 2.060
52-Week Range	1.910 - 4.900
Beta	0.83
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 27, 2026

About Racura Oncology

Racura Oncology Ltd operates as a clinical-stage biopharmaceutical company in Australia. It develops RC220, a formulation of (E,E)-bisantrene, which is in Phase III clinical trial for the treatment of acute myeloid leukemia; Phase Ia/b clinical trial for the treatment of epidermal growth factor receptor-mutated non-small cell lung cancer; and Phase Ia/b clinical trial for the treatment of solid tumor cancers. The company was formerly known as Race Oncology Limited and changed its name to Racura Oncology Ltd in December 2025. Racura Oncology Ltd...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: RAC

Financial Performance

In fiscal year 2026, Racura Oncology's revenue was 2.81 million, a decrease of -46.50% compared to the previous year's 5.25 million. Losses were -11.09 million, 131.6% more than in 2025.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 17, 2026

Data Sources Report a data error